Other coagulation complications, such as arterial thrombosis (14% vs. 9%; p = 0.3) and haemorrhage (9% vs. 5%; p = 0.3), were not significantly different in patients with ET with JAK2 mutations than those with CALR mutations. This evidence concerns the gene JAK2 and Arterial thrombosis.